Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • 2019
  • Chapter
  • Economic Dimensions of Personalized and Precision Medicine

Characterizing the Drug Development Pipeline for Precision Medicines

By: Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
  • Format:Print
ShareBar

Abstract

BOOK ABSTRACT: Personalized and precision medicine (PPM)—the targeting of therapies according to an individual’s genetic, environmental, or lifestyle characteristics—is becoming an increasingly important approach in health care treatment and prevention. The advancement of PPM is a challenge in traditional clinical, reimbursement, and regulatory landscapes because it is costly to develop and introduces a wide range of scientific, clinical, ethical, and socioeconomic issues. PPM raises a multitude of economic issues, including how information on accurate diagnosis and treatment success will be disseminated and who will bear the cost; changes to physician training to incorporate genetics, probability and statistics, and economic considerations; questions about whether the benefits of PPM will be confined to developed countries or will diffuse to emerging economies with less developed health care systems; the effects of patient heterogeneity on cost-effectiveness analysis; and opportunities for PPM’s growth beyond treatment of acute illness, such as prevention and reversal of chronic conditions. This volume explores the intersection of the scientific, clinical, and economic factors affecting the development of PPM, including its effects on the drug pipeline, on reimbursement of PPM diagnostics and treatments, and on funding the requisite underlying research. The research also examines recent empirical applications of PPM.

Keywords

Healthcare; Precision Medicine

Citation

Chandra, Amitabh, Craig Garthwaite, and Ariel Dora Stern. "Characterizing the Drug Development Pipeline for Precision Medicines." Chap. 5 in Economic Dimensions of Personalized and Precision Medicine, edited by Ernest R. Berndt, Dana P. Goldman, and John W. Rowe, 115–158. University of Chicago Press, 2019.

About The Authors

Amitabh Chandra

Technology and Operations Management
→More Publications

Ariel D. Stern

Technology and Operations Management
→More Publications

More from the Authors

    • May 9, 2023
    • JAMA, the Journal of the American Medical Association

    Regulatory Submission Characteristics and Recalls of Medical Devices Receiving 510(k) Clearance

    By: Alexander O. Everhart, Yi Zhu and Ariel D. Stern
    • April 2023
    • Faculty Research

    Elliott Management: Capital Allocation in Biopharma

    By: Amitabh Chandra, Paul Clancy and Lauren Gunasti
    • February 2023
    • Faculty Research

    The Brigham and Women’s Hospital Innovation Hub: Driving Internal Innovation

    By: Ariel Dora Stern, Robert S. Huckman and Sarah Mehta
More from the Authors
  • Regulatory Submission Characteristics and Recalls of Medical Devices Receiving 510(k) Clearance By: Alexander O. Everhart, Yi Zhu and Ariel D. Stern
  • Elliott Management: Capital Allocation in Biopharma By: Amitabh Chandra, Paul Clancy and Lauren Gunasti
  • The Brigham and Women’s Hospital Innovation Hub: Driving Internal Innovation By: Ariel Dora Stern, Robert S. Huckman and Sarah Mehta
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College